(Q45411000)

14 December 2017

title

Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation (English)

1 reference

14 December 2017

main subject

liver transplantation

1 reference

1 reference

1 reference

Umeda M

1

1 reference

14 December 2017

Marusawa H

2

1 reference

14 December 2017

Ueda M

3

1 reference

14 December 2017

Takada Y

4

1 reference

14 December 2017

Egawa H

5

1 reference

14 December 2017

Uemoto S

6

1 reference

14 December 2017

Chiba T

7

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

American Journal of Transplantation

14 December 2017

published in

1 reference

14 December 2017

volume

6

1 reference

14 December 2017

issue

11

1 reference

14 December 2017

page(s)

2680-2685

1 reference

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

"Occult" hepatitis B virus as source of infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Lamivudine treatment for acute hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01542.X

10.1111/J.1600-6143.2006.01542.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference